In the spring of 2014, a search of the clinicaltrials.gov web site with the key words acute myeloid leukemia and phase II, III returned a list of just over 340 open studies. Most of those trials involving novel agents can be grouped into 1 of 2 general categories: immunomodulators or kinase inhibitors.
Follicular lymphoma is the malignancy of germinal center B cells in the lymph nodes. It is the second most commonly diagnosed non-Hodgkinâ€™s lymphoma, accounting for approximately 35% of all such cases.
Creating new treatment options for CLL, particularly for high-risk patient populations such as those with fludarabine-refractory disease or with 17p deletions, is the goal of an intense effort by clinical researchers and pharmaceutical companies.